The National Comprehensive Cancer Network guidelines (26) and the Chinese Society of Clinical Oncology (27) recommend immunotherapy combined with chemotherapy as the first-line treatment for PD-L1-positive NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.